Skip to main content

Table 3 Absolute and relative differences in mean dose and BED between sequential boost and the simultaneous integrated boost using the same prescribed biologically effective dose with α/β = 10 Gy (BED10) and 3 Gy (BED3) for all structures of the ten studied patients (mean ± SD)

From: Comparison of breast sequential and simultaneous integrated boost using the biologically effective dose volume histogram (BEDVH)

 

Dose (Gy)

(SIB10/SEQ–1) × 100

Dose (Gy)

(SIB3/SEQ–1) × 100

Dose (%)

BED10 (%)

Dose (%)

BED3 (%)

PTVboost

−1.5 ± 0.7

−2 ± 1

0 ± 1

−3.0 ± 0.7

−5 ± 1

0 ± 2

PTVbreast

−1.3 ± 0.8

−2 ± 1

−3 ± 1 a

−0.6 ± 0.9

−1 ± 2

−2 ± 2 a

ILung

−0.7 ± 0.4

−8 ± 4

−10 ± 4 a

−0.8 ± 0.5

−9 ± 4

−11 ± 4 a

CBreast

−0.1 ± 0.3

−6 ± 16

−6 ± 17

−0.1 ± 0.3

−5 ± 15

−6 ± 16

CLung

−0.1 ± 0.1

−7 ± 13

−8 ± 14

−0.1 ± 0.2

−6 ± 17

−7 ± 18

Heartleft b

−0.3 ± 0.5

−10 ± 16

−12 ± 16

−0.2 ± 0.1

−6 ± 4

−8 ± 4 a

Heartright c

−0.3 ± 0.4

−12 ± 17

−14 ± 19

−0.2 ± 0.6

−8 ± 24

−10 ± 25

  1. aIndicates a significant difference (p <0.05) between the SEQ and SIB plans in term of BED
  2. bGroup of 6 patients with left-sided breast tumor
  3. cGroup of 4 patients with right-sided breast tumor